SCHEMBL2499036

SCHEMBL2499036

C[C@H](O)c1ccc(Cc2c(OC(F)F)cccc2C(=O)O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.40
FAAH O00519 1/20 0.39
CNR2 P34972 1/20 0.39
TAS2R14 Q9NYV8 1/20 0.38
RORC P51449 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ALDH1A1 P00352 4/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 2/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 2/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TEAD4 Q15561 1/20 0.34
PLA2G1B P04054 1/20 0.34
ATG4B Q9Y4P1 1/20 0.34
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2498232 0.81 TSHR (0.35) ALDH1A1LMNATDP1KMT2ATSHR
SCHEMBL2497448 0.74 NOTUM (0.36) FAAHCNR2ALDH1A1HPGDHSD17B10
SCHEMBL6307911 0.70 FAAH (0.58) FAAHCNR2ALDH1A1HTTKDM4E
SCHEMBL27988953 0.69 CYP1A2 (0.53) ALDH1A1LMNAMAPTKDM4EHPGD
SCHEMBL2499033 0.69 TSHR (0.46) PDE4ATAS2R14SMN1; SMN2ALDH1A1LMNA
SCHEMBL975946 0.69 KDM4E (0.55) TAS2R14SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL27051923 0.68 ALB (0.52) TAS2R14SMN1; SMN2ALDH1A1MAPTTDP1
SCHEMBL27051918 0.67 MAPK1 (0.49) CNR2TAS2R14ALDH1A1LMNAMAPT
SCHEMBL16462074 0.67 TSHR (0.52) TAS2R14SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL31388741 0.67 TAS2R14 (0.48) TAS2R14SMN1; SMN2ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 PDE4A 1831/4885FAAH 3396/4885CNR2 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.